Results from the Phase 2 PHAROS trial potentially establish new benchmark with targeted combination therapies for this patient population
The expansion underscores Merck’s commitment to invest more than $70 billion in U.S. research, development and capital projects
Vamikibart is the first targeted, non-steroid treatment designed to address the underlying inflammation driving UME
This new facility strengthens Latin America as a collaborative hub
With this expansion, the overall fermentation capacity of the company has increased from 450 KL to 990 KL
Novelix will provide financial and infrastructural support for the entire technology transfer and scale-up program
This new suite of products demonstrates Nouryon’s leadership in cleaning ingredient solutions
The new cGMP-compliant HPAPI Laboratory is equipped with state-of-the-art isolators designed to meet Occupational Exposure Band 5 (OEB-5) requirements
Anil Gupta has been appointed as the Senior Vice President, and Sanjay Singhania has taken charge as the Vice President of PHDCCI
Updated indication expands treatment options for patients with ulcerative colitis and Crohn’s disease when tumor necrosis factor (TNF) blockers are clinically inadvisable
Subscribe To Our Newsletter & Stay Updated
